Sales of Merck’s Keytruda rose 89.2 percent to $1.67 billion, edging past sales of its rival immunotherapy Opdivo made by Bristol-Myers Squibb.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.